Skip to main content
SpringerLink
Log in

Efficacy and Safety of Donepezil in Patients with Alzheimer’s Disease

Results of a Global, Multinational, Clinical Experience Study

  • Original Research Article
  • Published:
Drugs & Aging Aims and scope Submit manuscript

Abstract

Background

Donepezil has consistently been shown to be effective and well tolerated in the symptomatic treatment of Alzheimer’s disease in placebo-controlled clinical trials. It has been shown to provide significant benefits in cognition, global function and activities of daily living in patients with mild-to-moderate Alzheimer’s disease. However, in order to control for confounding factors, some clinical trials of donepezil have excluded patients with comorbid illness and concomitant medication use.

Objective

The objective of this study was to evaluate the efficacy, tolerability and safety of donepezil in a wider and more diverse sample of patients and centres than previous trials, reflecting routine clinical practice.

Methods

In this 12-week, open-label, multicentre trial, patients with probable mild-to-moderate Alzheimer’s disease received donepezil 5 mg/day for 28 days, after which the dosage was increased to 10 mg/day according to the investigating clinician’s judgement. Patients were enrolled at 246 study centres in 18 countries worldwide. Cognition was assessed by a trained clinician using the Mini-Mental State Examination (MMSE) at baseline, week 4 and week 12 (or last visit). Changes in patient activity and social interaction were evaluated using a caregiver diary. Each week, caregivers recorded their impression of change compared with baseline on three aspects of patient behaviour using a 5-point scale. Efficacy analyses were performed on the intent-to-treat population. Significance was determined using the paired t-test (0.05 significance level). Tolerability and safety were assessed by monitoring adverse events, physical examinations, vital signs, clinical laboratory test abnormalities and ECG findings throughout the study.

Results

A total of 1113 patients received donepezil (mean baseline MMSE score [±SD] 18.74 ± 5.21). 989 (88.9%) patients completed the study; 59 (5%) patients discontinued because of adverse events. Most patients were taking at least one concomitant medication (n = 802; 72%) and had at least one comorbid medical condition (n = 745; 67%) on study entry. Donepezil significantly improved cognition compared with baseline at weeks 4 and 12, and at week 12 using a last observation carried forward (LOCF) analysis (all p < 0.0001). Mean change from baseline MMSE score (±SE) at week 12-LOCF was +1.73 ± 0.10. Donepezil was also associated with significant improvements in patient social interaction, engagement and interest, and initiation of pleasurable activities at all weekly assessments and week 12-LOCF (all p < 0.0001). Donepezil was generally well tolerated; adverse events were consistent with the known safety profile of donepezil.

Conclusion

Donepezil treatment resulted in statistically significant improvements in cognition and patient activity and social behaviour, and was generally well tolerated despite high levels of comorbid illness and concomitant medication use. The results of this open-label study in a large patient population are consistent with those from controlled trials and support that donepezil is effective in the treatment of mild-to-moderate Alzheimer’s disease in everyday practice.

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

Table I
Table II
Table III
Fig. 1
Fig. 2
Fig. 3
Table IV

Similar content being viewed by others

References

  1. Dunkin JJ, Anderson-Hanley C. Dementia caregiver burden: a review of the literature and guidelines for assessment and intervention. Neurology 1998; 51(1 Suppl.): S53–60

    Article  PubMed  CAS  Google Scholar 

  2. O’Donnell BF, Drachman DA, Barnes HJ, et al. Incontinence and troublesome behaviors predict institutionalization in dementia. J Geriatr Psychiatry Neurol 1992; 5(1): 45–52

    PubMed  Google Scholar 

  3. Becker RE. Therapy of the cognitive deficit in Alzheimer’s disease: the cholinergic system. In: Becker RE, Giacobini E, editors. Cholinergic basis for Alzheimer therapy. Boston (MA): Birkhauser, 1991: 1–22

    Google Scholar 

  4. Levy ML, Cummings JL, Kahn-Rose R. Neuropsychiatric symptoms and cholinergic therapy for Alzheimer’s disease. Gerontology 1999; 45(1 Suppl.): 15–22

    Article  PubMed  CAS  Google Scholar 

  5. Francis PT, Palmer AM, Snape M, et al. The cholinergic hypothesis of Alzheimer’s disease: a review of progress. J Neurol Neurosurg Psychiatry 1999; 66(21): 137–47

    Article  PubMed  CAS  Google Scholar 

  6. Rosier M, Anand R, Cicin-Sain A, et al. Efficacy and safety of rivastigmine in patients with Alzheimer’s disease: international randomised controlled trial. BMJ 1999; 318(7184): 633–8

    Google Scholar 

  7. Tariot PN, Solomon PR, Morris JC, et al. A 5-month, randomized, placebo-controlled trial of galantamine in AD: the Galantamine USA-10 Study Group. Neurology 2000; 54(12): 2269–76

    Article  PubMed  CAS  Google Scholar 

  8. Rogers SL, Doody RS, Mohs RC, et al. Donepezil improves cognition and global function in Alzheimer’s disease: a 15-week, double-blind, placebo-controlled study. Donepezil Study Group. Arch Intern Med 1998; 158(9): 1021–31

    Article  PubMed  CAS  Google Scholar 

  9. Rogers SL, Farlow MR, Doody RE, et al. A 24-week, double-blind, placebo-controlled trial of donepezil in patients with Alzheimer’s disease. Neurology 1998; 50(1): 136–45

    Article  PubMed  CAS  Google Scholar 

  10. Kurz A. Managing the burden of Alzheimer’s disease: a partnership between caregiver and physician. Eur J Neurol 1998; 5(4 Suppl.): S1–8

    Article  Google Scholar 

  11. Petry S, Cummings JL, Hill MA, et al. Personality alterations in dementia of the Alzheimer type. Arch Neurol 1988; 45(11): 1187–90

    Article  PubMed  CAS  Google Scholar 

  12. Rubin EH, Morris JC, Storandt M, et al. Behavioral changes in patients with mild senile dementia of the Alzheimer’s type. Psychiatry Res 1987; 21(1): 55–62

    Article  PubMed  CAS  Google Scholar 

  13. Burns A, Rossor M, Hecker J, et al. The effects of donepezil in Alzheimer’s disease: results from a multinational trial. Dement Geriatr Cogn Disord 1999; 10(3): 237–44

    Article  PubMed  CAS  Google Scholar 

  14. Mohs RC, Doody RS, Morris JC, et al. A 1-year, placebo-controlled preservation of function survival study of donepezil in AD patients. Neurology 2001; 57(3): 481–8

    Article  PubMed  CAS  Google Scholar 

  15. Winblad B, Engedal K, Soininen H, et al. A 1-year, randomized, placebo-controlled study of donepezil in patients with mild to moderate AD. Neurology 2001; 57(3): 489–95

    Article  PubMed  CAS  Google Scholar 

  16. Wimo A, Winblad B, Engedal K, et al. An economic evaluation of donepezil in mild to moderate Alzheimer’s disease: results of a one-year, double-blind, randomized trial. Dement Geriatr Cogn Disord 2003; 15(1): 44–54

    Article  PubMed  CAS  Google Scholar 

  17. Feldman H, Gauthier S, Hecker J, et al. A 24-week randomized, double-blind study of donepezil in moderate to severe Alzheimer’s disease. Neurology 2001; 57(4): 613–20

    Article  PubMed  CAS  Google Scholar 

  18. Eisai Ltd. Aricept® (donepezil hydrochloride tablets): summary of product characteristics [prescribing information]. London, 2002

    Google Scholar 

  19. Eisai Inc. Aricept® (donepezil hydrochloride tablets). US package insert. Teaneck (NJ), USA, 2000

    Google Scholar 

  20. Doody RS, Geldmacher DS, Gordon B, et al. Open-label, multicenter, phase 3 extension study of the safety and efficacy of donepezil in patients with Alzheimer disease. The Donepezil Study Group. Arch Neurol 2001; 58(3): 427–33

    Article  PubMed  CAS  Google Scholar 

  21. Rogers SL, Friedhoff LT. Long-term efficacy and safety of donepezil in the treatment of Alzheimer’s disease: an interim analysis of the results of a US multicentre open label extension study. Eur Neuropsychopharmacol 1998; 8(1): 67–75

    Article  PubMed  CAS  Google Scholar 

  22. Data on file, Pfizer Inc., 2003

  23. Relkin NR, Reichman WE, Orazem J, et al. A large, community-based, open-label trial of donepezil in the treatment of Alzheimer’s disease. Dement Geriatr Cogn Disord 2003; 16(1): 15–24

    Article  PubMed  CAS  Google Scholar 

  24. American Psychiatric Association. Diagnostic and statistical manual of mental health disorder (DSM-IV-R). 4th ed. rev. Washington, DC, USA: American Psychiatric Association, 1994

    Google Scholar 

  25. McKhann G, Drachman D, Folstein M, et al. Clinical diagnosis of Alzheimer’s disease: report of the NINCDS-ADRDA Work Group under the auspices of Department of Health and Human Services Task Force on Alzheimer’s Disease. Neurology 1984; 34(7): 939–44

    Article  PubMed  CAS  Google Scholar 

  26. Folstein MF, Folstein SE, McHugh PR. “Mini-Mental State”: a practical method for grading the cognitive state of patients, for the clinician. J Psychiatr Res 1975; 12(3): 189–98

    Article  PubMed  CAS  Google Scholar 

  27. Feldman H, Gauthier S, Hecker J, et al. Efficacy of donepezil on maintenance of activities of daily living in patients with moderate to severe Alzheimer’s disease and the impact on caregiver burden. J Am Geriatr Soc 2003; 51(6): 737–44

    Article  PubMed  Google Scholar 

  28. Galasko D, Bennet D, Sano M, et al. An inventory to assess activities of daily living for clinical trials in patients with Alzheimer’s disease. Alzheimer Dis Assoc Disord 1997; 11(2 Suppl.): S33–9

    Article  PubMed  Google Scholar 

  29. Hecker J, Brodaty H, Australian Donepezil Study Group, et al. Efficacy and safety of donepezil in patients with Alzheimer’s disease: preliminary findings from the Australian subset of a global clinical experience study. Eur Neuropsychopharmacol 2000; 10(3 Suppl.): S367

    Google Scholar 

  30. Cummings JL, Kaufer D. Neuropsychiatric aspects of Alzheimer’s disease: the cholinergic hypothesis revisited. Neurology 1996; 47(4): 876–83

    Article  PubMed  CAS  Google Scholar 

  31. Craig AH, Cummings JL, Fairbanks L, et al. Cerebral blood flow correlates of apathy in Alzheimer disease. Arch Neurol 1996; 53(11): 1116–20

    Article  PubMed  CAS  Google Scholar 

  32. Damasio H, Eslinger P, Damasio AR, et al. Quantitative computed tomographic analysis in the diagnosis of dementia. Arch Neurol 1983; 40(12): 715–9

    Article  PubMed  CAS  Google Scholar 

Download references

Acknowledgements

This study was sponsored by Pfizer Pharmaceuticals Group, Pfizer Inc., New York, USA. Professor Henry Brodaty has received honoraria, clinical trial support, consultancy fees and grants from Pfizer Inc. and Eisai Inc.; Professor Patrick Cras has received honoraria from Pfizer Inc.; Professor Murat Emre has received clinical trial support from Pfizer Inc. and Novartis; Dr Richard Zhang and Dr Ranbir Bahra are employees of Pfizer Inc. The authors would like to thank the investigators listed in the appendix who participated in this study and contributed to the study conduct or design.

Author information

Authors and Affiliations

  1. Fundació ACE, Barcelona, Spain

    Mercè Boada-Rovira

  2. Academic Department for Old Age Psychiatry, School of Psychiatry, University of New South Wales, Sydney, Australia

    Henry Brodaty

  3. Department of Neurology, University Hospital of Antwerp, Antwerp, Belgium

    Patrick Cras

  4. AHEPA Hospital A’Neurological University Clinic, Thessaloniki, Greece

    Stavros Baloyannis

  5. Department of Neurology, Istanbul University, Istanbul, Turkey

    Murat Emre

  6. Pfizer Pharmaceuticals Group, Pfizer Inc., 235 East 42nd Street, New York, NY, 10017-5755, USA

    Richard Zhang &  Ranbir Bahra

Authors
  1. Mercè Boada-Rovira
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. Henry Brodaty
    View author publications

    You can also search for this author in PubMed Google Scholar

  3. Patrick Cras
    View author publications

    You can also search for this author in PubMed Google Scholar

  4. Stavros Baloyannis
    View author publications

    You can also search for this author in PubMed Google Scholar

  5. Murat Emre
    View author publications

    You can also search for this author in PubMed Google Scholar

  6. Richard Zhang
    View author publications

    You can also search for this author in PubMed Google Scholar

  7. Ranbir Bahra
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to Ranbir Bahra.

Rights and permissions

Reprints and permissions

About this article

Cite this article

Boada-Rovira, M., Brodaty, H., Cras, P. et al. Efficacy and Safety of Donepezil in Patients with Alzheimer’s Disease. Drugs Aging 21, 43–53 (2004). https://doi.org/10.2165/00002512-200421010-00004

Download citation

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.2165/00002512-200421010-00004

Keywords

Search

Navigation